The effectiveness of tyrosine kinase inhibitor for chronic myeloid leukemia in tuberous sclerosis. A case report and review of literature. Issue 3 (17th March 2023)

• Record Type: Journal Article
• Authors: Al‐Abdulmalek, Abdulrahman; Al‐Suliman, Reem; Abu‐Tineh, Mohammad; Ali, Mostafa; Yassin, Mohamed A.
• Is Part Of: Clinical case reports. Volume 11:Issue 3(2023)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2023-03-17
• Subjects: CML -- tuberous sclerosis -- tyrosine kinase inhibitors; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.7087
• Languages: English
• ISSNs: 2050-0904

Abstract

Abstract: The relationship between chronic myelogenous leukemia (CML) and tuberous sclerosis (TS) is unusual and uncommon. Here, we report a 24‐year‐old woman diagnosed with TS and later identified with CML, as the second case reported with such coexistence, treated with Nilotinib. This article proposes a hypothesis to explain the association. Therefore, we propose Nilotinib for the treatment of patients with such coexisting diseases. Further studies are warranted to reveal the dynamics between these conditions.